229 related articles for article (PubMed ID: 21632858)
1. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.
Koukourakis MI; Giatromanolaki A; Sivridis E; Gatter KC; Trarbach T; Folprecht G; Shi MM; Lebwohl D; Jalava T; Laurent D; Meinhardt G; Harris AL
Clin Cancer Res; 2011 Jul; 17(14):4892-900. PubMed ID: 21632858
[TBL] [Abstract][Full Text] [Related]
2. Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.
Giatromanolaki A; Koukourakis MI; Sivridis E; Gatter KC; Trarbach T; Folprecht G; Shi MM; Lebwohl D; Jalava T; Laurent D; Meinhardt G; Harris AL;
Br J Cancer; 2012 Sep; 107(7):1044-50. PubMed ID: 22910317
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
Wilson PM; Yang D; Azuma M; Shi MM; Danenberg KD; Lebwohl D; Sherrod A; Ladner RD; Zhang W; Danenberg PV; Trarbach T; Folprecht G; Meinhardt G; Lenz HJ
Pharmacogenomics J; 2013 Oct; 13(5):410-6. PubMed ID: 22664478
[TBL] [Abstract][Full Text] [Related]
4. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours.
Scott EN; Meinhardt G; Jacques C; Laurent D; Thomas AL
Expert Opin Investig Drugs; 2007 Mar; 16(3):367-79. PubMed ID: 17302531
[TBL] [Abstract][Full Text] [Related]
5. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
[TBL] [Abstract][Full Text] [Related]
6. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
Koukourakis MI; Giatromanolaki A; Sivridis E; Gatter KC; Harris AL;
J Clin Oncol; 2006 Sep; 24(26):4301-8. PubMed ID: 16896001
[TBL] [Abstract][Full Text] [Related]
7. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
Bar J; Spencer S; Morgan S; Brooks L; Cunningham D; Robertson J; Jürgensmeier JM; Goss GD
Clin Colorectal Cancer; 2014 Mar; 13(1):46-53. PubMed ID: 24355210
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
9. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
Scartozzi M; Giampieri R; Maccaroni E; Del Prete M; Faloppi L; Bianconi M; Galizia E; Loretelli C; Belvederesi L; Bittoni A; Cascinu S
Br J Cancer; 2012 Feb; 106(5):799-804. PubMed ID: 22315053
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible proteins HIF1α and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer.
Koukourakis MI; Kakouratos C; Kalamida D; Bampali Z; Mavropoulou S; Sivridis E; Giatromanolaki A
Int J Radiat Biol; 2016 Jul; 92(7):353-63. PubMed ID: 27010533
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
Jost LM; Gschwind HP; Jalava T; Wang Y; Guenther C; Souppart C; Rottmann A; Denner K; Waldmeier F; Gross G; Masson E; Laurent D
Drug Metab Dispos; 2006 Nov; 34(11):1817-28. PubMed ID: 16882767
[TBL] [Abstract][Full Text] [Related]
12. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial.
Tyagi P
Clin Colorectal Cancer; 2005 May; 5(1):24-6. PubMed ID: 15929803
[No Abstract] [Full Text] [Related]
13. Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1.
Kayser G; Kassem A; Sienel W; Schulte-Uentrop L; Mattern D; Aumann K; Stickeler E; Werner M; Passlick B; zur Hausen A
Diagn Pathol; 2010 Apr; 5():22. PubMed ID: 20385008
[TBL] [Abstract][Full Text] [Related]
14. Lactate dehydrogenase 5 expression in Non-Hodgkin lymphoma is associated with the induced hypoxia regulated protein and poor prognosis.
Lu R; Jiang M; Chen Z; Xu X; Hu H; Zhao X; Gao X; Guo L
PLoS One; 2013; 8(9):e74853. PubMed ID: 24086384
[TBL] [Abstract][Full Text] [Related]
15. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
Los M; Roodhart JM; Voest EE
Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
[TBL] [Abstract][Full Text] [Related]
16. High lactate dehydrogenase 5 expression correlates with high tumoral and stromal vascular endothelial growth factor expression in gastric cancer.
Kim HS; Lee HE; Yang HK; Kim WH
Pathobiology; 2014; 81(2):78-85. PubMed ID: 24401755
[TBL] [Abstract][Full Text] [Related]
17. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.
Silvestris N; Scartozzi M; Graziano G; Santini D; Lorusso V; Maiello E; Barni S; Cinieri S; Loupakis F; Pisconti S; Brunetti AE; Palasciano G; Palmieri VO; Del Prete M; Dell'Aquila E; Latiano TP; Petrelli F; Lutrino S; Rossini D; Giampieri R; Lotesoriere C; Cascinu S
Expert Opin Biol Ther; 2015 Feb; 15(2):155-62. PubMed ID: 25411089
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance and prognostic value of lactate dehydrogenase A expression in gastric cancer patients.
Sun X; Sun Z; Zhu Z; Guan H; Zhang J; Zhang Y; Xu H; Sun M
PLoS One; 2014; 9(3):e91068. PubMed ID: 24608789
[TBL] [Abstract][Full Text] [Related]
19. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer.
Koukourakis MI; Giatromanolaki A; Simopoulos C; Polychronidis A; Sivridis E
Clin Exp Metastasis; 2005; 22(1):25-30. PubMed ID: 16132575
[TBL] [Abstract][Full Text] [Related]
20. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
Drevs J; Zirrgiebel U; Schmidt-Gersbach CI; Mross K; Medinger M; Lee L; Pinheiro J; Wood J; Thomas AL; Unger C; Henry A; Steward WP; Laurent D; Lebwohl D; Dugan M; Marmé D
Ann Oncol; 2005 Apr; 16(4):558-65. PubMed ID: 15705616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
